Search research articles
Contact Us
Filters
Showing results (61-70 of 87) with videos related to
Page
of 9
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
November 14, 2014
Increased anti-KIR4.1 antibodies in multiple sclerosis: could it be a marker of disease relapse?
Livnat Brill, Lotem Goldberg, Arnon Karni, et al.
Frontiers in Neurology
|
February 15, 2021
Age-Related Clinical Presentation of MOG-IgG Seropositivity in Israel
Livnat Brill, Esther Ganelin-Cohen, Ron Dabby, et al.
JAMA Neurology
|
September 23, 2021
Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab
Livnat Brill, Ariel Rechtman, Omri Zveik, et al.
Brain, Behavior, and Immunity
|
May 8, 2020
Lack of association between unipolar or bipolar depression and serum aquaporin-4 autoantibodies
Shay Gur, Michal Taler, Gil Bormant, et al.
Journal of Immunology Research
|
June 29, 2018
NMO-IgG and AQP4 Peptide Can Induce Aggravation of EAMG and Immune-Mediated Muscle Weakness
Tehila Mizrachi, Livnat Brill, Malcolm Rabie, et al.
Multiple Sclerosis and Related Disorders
|
January 15, 2026
Chronic stress amplifies multidimensional disease activity in multiple sclerosis patients: A year-long within-person analysis
Omri Zveik-Lavi, Dvir Green, Ariel Rechtman, et al.
Immunology and Cell Biology
|
December 11, 2020
Alemtuzumab mediates the CD39<sup>+</sup> T-regulatory cell response via CD23<sup>+</sup> macrophages
Lital Remez, Esther Ganelin-Cohen, Dina Safina, et al.
Journal of Neuroimmunology
|
April 7, 2016
Increased occurrence of anti-AQP4 seropositivity and unique HLA Class II associations with neuromyelitis optica (NMO), among Muslim Arabs in Israel
Livnat Brill, Micha Mandel, Dimitrios Karussis, et al.
Therapeutic Advances in Neurological Disorders
|
August 6, 2025
National guidelines for diagnosis, treatment, and management of myasthenia gravis in Israel
Shahar Shelly, Marc Gotkine, Adi Wilf Yarkoni, et al.
Multiple Sclerosis and Related Disorders
|
September 9, 2022
Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel
Janick Weberpals, Spyros Roumpanis, Yael Barer, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 87) with videos related to
Sort By:
Page
of 9
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
November 14, 2014
Increased anti-KIR4.1 antibodies in multiple sclerosis: could it be a marker of disease relapse?
Livnat Brill, Lotem Goldberg, Arnon Karni, et al.
Frontiers in Neurology
|
February 15, 2021
Age-Related Clinical Presentation of MOG-IgG Seropositivity in Israel
Livnat Brill, Esther Ganelin-Cohen, Ron Dabby, et al.
JAMA Neurology
|
September 23, 2021
Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab
Livnat Brill, Ariel Rechtman, Omri Zveik, et al.
Brain, Behavior, and Immunity
|
May 8, 2020
Lack of association between unipolar or bipolar depression and serum aquaporin-4 autoantibodies
Shay Gur, Michal Taler, Gil Bormant, et al.
Journal of Immunology Research
|
June 29, 2018
NMO-IgG and AQP4 Peptide Can Induce Aggravation of EAMG and Immune-Mediated Muscle Weakness
Tehila Mizrachi, Livnat Brill, Malcolm Rabie, et al.
Multiple Sclerosis and Related Disorders
|
January 15, 2026
Chronic stress amplifies multidimensional disease activity in multiple sclerosis patients: A year-long within-person analysis
Omri Zveik-Lavi, Dvir Green, Ariel Rechtman, et al.
Immunology and Cell Biology
|
December 11, 2020
Alemtuzumab mediates the CD39<sup>+</sup> T-regulatory cell response via CD23<sup>+</sup> macrophages
Lital Remez, Esther Ganelin-Cohen, Dina Safina, et al.
Journal of Neuroimmunology
|
April 7, 2016
Increased occurrence of anti-AQP4 seropositivity and unique HLA Class II associations with neuromyelitis optica (NMO), among Muslim Arabs in Israel
Livnat Brill, Micha Mandel, Dimitrios Karussis, et al.
Therapeutic Advances in Neurological Disorders
|
August 6, 2025
National guidelines for diagnosis, treatment, and management of myasthenia gravis in Israel
Shahar Shelly, Marc Gotkine, Adi Wilf Yarkoni, et al.
Multiple Sclerosis and Related Disorders
|
September 9, 2022
Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel
Janick Weberpals, Spyros Roumpanis, Yael Barer, et al.
Page
of 9